Low-Dose Oral Minoxidil Improves Hairline and Eyebrow Coverage in Frontal Fibrosing Alopecia: A Prospective Study [0.03%]
低剂量口服米诺地尔可改善前额纤维性斑秃患者的发际线及眉毛覆盖率：一项前瞻性研究
Diego Henrique Morais Silva,Mercedes Cristina Mongelli Martin Paro,Gustavo Baptista de Almeida Faro et al.
Diego Henrique Morais Silva et al.
Introduction: Frontal fibrosing alopecia (FFA) is a primary lymphocytic scarring alopecia that commonly presents with frontotemporal hairline recession and eyebrow loss. While most treatments aim to control inflammation a...
Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional Studies [0.03%]
真实世界中治疗银屑病的Tildrakizumab研究（T-REX）：四项非干预性研究的 meta分析
Athanasios Tsianakas,Nina Magnolo,Afra Kempf et al.
Athanasios Tsianakas et al.
Introduction: Tildrakizumab, an anti-IL-23p19 antibody, is registered for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Its effectiveness in specific patient sub...
Lipidomic Insights into Seborrheic Dermatitis: Clinical Evaluation of Sebum Changes Using SpiderMass [0.03%]
脂质组学视角下的脂溢性皮炎研究：使用SpiderMass技术评估皮脂变化的临床评价
Lucille Darras,Célia Ipinazar,Eléonore Gravier et al.
Lucille Darras et al.
Introduction: Seborrheic dermatitis (SD) is a skin disorder in which chronic inflammation of the scalp is linked to excessive sebum production and overgrowth of Malassezia fungi. These fungi break down sebum lipids, relea...
Validation of Self-Reported Vitiligo Prevalence among Adults in the USA and Europe Using the 2024 National Health and Wellness Survey [0.03%]
利用2024年国家健康与幸福调查验证美国和欧洲成年人自报的白癜病房患率
Seemal R Desai,Khaled Ezzedine,Markus Böhm et al.
Seemal R Desai et al.
Introduction: Vitiligo is a chronic depigmenting autoimmune skin disease that may be associated with a significant quality-of-life burden and psychosocial comorbidities. Reliable and comparable prevalence rates are critic...
A Retrospective Real-World Comparison of Topical Delgocitinib and Localized Cream Psoralen-Ultraviolet A in Chronic Hand Eczema [0.03%]
度美莫司与局部皮质类固醇治疗慢性手部湿疹的回顾性真实世界对比研究
Stefan Weißinger,Eva Oppel,Nils Kurzen et al.
Stefan Weißinger et al.
Introduction: Chronic hand eczema (CHE) remains difficult to treat, particularly in patients unresponsive or intolerant to topical corticosteroids. Although topical delgocitinib, the first topical JAK inhibitor approved f...
HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study [0.03%]
HS-20137治疗中度至重度银屑病的二期随机双盲临床试验
Lin Cai,Xiaohua Wang,Litao Zhang et al.
Lin Cai et al.
Introduction: HS-20137 is a novel interleukin-23 inhibitor and is suggested to be effective for the treatment of psoriasis in a phase 1b study. Our study aimed to evaluate the efficacy and safety of HS-20137 in patients w...
Efficacy of Remibrutinib versus Dupilumab at Early Timepoints in Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM) [0.03%]
Remibrutinib与Dupilumab治疗慢性自发性荨麻疹的疗效：美国III期研究设计(RECLAIM)
Gil Yosipovitch,Giselle Mosnaim,Christine-Elke Ortmann et al.
Gil Yosipovitch et al.
Introduction: Remibrutinib, an oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor, was recently approved by the US Food and Drug Administration (FDA) for the treatment of chronic spontaneous urticaria (CSU). ...
Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications [0.03%]
重度斑秃循环miRNA特征的诊断鉴别、通路分析及治疗意义
Jesús Gay-Mimbrera,Macarena Aguilar-Luque,Pedro J Gómez-Arias et al.
Jesús Gay-Mimbrera et al.
Introduction: Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss due to immune dysregulation. Despite advances, its precise molecular mechanisms remain unclear. This study investigates ...
Marta Kasprowicz-Furmańczyk,Ilona Tadulewicz,Agnieszka Markiewicz et al.
Marta Kasprowicz-Furmańczyk et al.
Lichen sclerosus is a chronic inflammatory disease of the skin and mucous membranes of unknown etiology. The disease most often affects the genital area, but the extragenital form of the disease is diagnosed in approximately 15-20% of patie...
Understanding Clinical Inertia in Atopic Dermatitis: A Mixed-Methods Study of Barriers to Treatment Escalation [0.03%]
特应性皮炎治疗升级的临床惰性及其障碍因素：一项综合研究
Michael Hindelang,Daria Klimova,Arnau Domenech et al.
Michael Hindelang et al.
Introduction: Although effective therapies are available for moderate-to-severe atopic dermatitis (AD), many eligible patients do not receive timely treatment escalation. This phenomenon, termed clinical inertia, is well ...